HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Aims To Triple “Breakthrough” Innovations With New Cost Savings

This article was originally published in The Rose Sheet

Executive Summary

During its Nov 15 analyst meeting, Procter & Gamble announces it will continue cutting staff in order to help finance new innovations, with plans to introduce three times more “breakthrough” innovations over the next five years than were achieved in the previous five years.

You may also be interested in...



P&G Targets $10 Billion In Cost Savings In Four Years

P&G will $10 billion in costs by the end of fiscal 2016, firm says at Analyst Group of New York Conference Feb. 23. Firm aims to derive $3 billion of that from reduced overhead, with plans to cut 5,700 jobs by the end of next fiscal year.

P&G/Pantene Debuts Plant-Based Hair-Care Packaging In Sustainability Race

Procter & Gamble’s Pantene unit is rolling out Pro-V Nature Fusion shampoo and conditioner products in primarily plant-based plastic bottles, demonstrating the firm’s leadership in an increasingly sustainable industry.

MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’

The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel